Efficacy Observation of Treatment of Mizolastine Combined with Total Glucosides of Paeony for Chronic Urticaria

Abstract:

Objective: To study the clinical efficacy and safety of the treatment of mizolastine combined with total glucosides of paeony for chronic urticaria, and to provide guidance for the future clinical treatment. Method: Eighty-four patients with chronic urticaria were randomized into the control group (10 mg mizolastine, once evening for 4 weeks) and the observation group (based on the control group, added 600 mg total glucosides of paeony capsules, twice daily for 4 weeks) of 42 patients per group. The clinical efficacy, recurrence rate and adverse reactions in the two groups were observed and compared according to the symptom score decreased index (SSRI). Result: Compared with the control group, the effective rate was significantly increased (90.5% vs 71.4%, P<0.05), the recurrence rate was obviously reduced (42.9% vs 71.4%, P<0.05), the SSRI scores were significantly decreased after treatment (0.7±0.2 vs 1.3±0.4, P<0.05), the serum IgE levels were significantly reduced after treatment[(82.5±13.6) vs (102.9±14.3) U·mL^-1, P<0.05] in the observation group. There were no obvious adverse reactions in the two groups during the treatment period. Conclusion: The treatment of mizolastine combined with total glucosides of paeony has significant efficacy and high safety for chronic urticaria, which is worthy of clinical promotion.